

Amendments to the Claims

Please amend the claims as follows:

1. (Previously presented): An immunogenic composition comprising IPV, a bacterial polysaccharide or oligosaccharide and a stabilizing agent, all formulated as a dried composition, which after reconstitution, is capable of generating an immune response against polio virus.
2. (Previously presented): The immunogenic composition of claim 1 comprising a capsular polysaccharide or oligosaccharide antigen from *Haemophilus influenzae* b.
3. (Previously presented): The immunogenic composition of claim 1 wherein the polysaccharide or oligosaccharide is conjugated to a carrier protein.
4. (Previously presented): The immunogenic composition of claim 3 wherein the polysaccharide or oligosaccharide is conjugated to tetanus toxoid.
5. (Previously presented): The immunogenic composition of claim 2 wherein the polysaccharide or oligosaccharide is adsorbed onto aluminium phosphate.
6. (Previously presented): The immunogenic composition of claim 1 comprising a capsular polysaccharide or oligosaccharide derived from *N. meningitidis* C.
7. (Previously presented): The immunogenic composition of claim 1 additionally comprising a capsular polysaccharide or oligosaccharide derived from any of *N. meningitidis* A, Y or W or combination thereof.

8. (Previously presented): The immunogenic composition of claim 6 wherein the meningococcal polysaccharides or oligosaccharides are conjugated to a carrier protein.

9. (Previously presented): The immunogenic composition of claim 8 comprising a *Haemophilus influenzae* b polysaccharide or oligosaccharide and at least one meningococcal polysaccharide or oligosaccharide conjugated to the same type of carrier protein.

10. (Previously presented): The immunogenic composition of claim 8 comprising a *Haemophilus influenzae* b polysaccharide or oligosaccharide and at least one meningococcal polysaccharide or oligosaccharide conjugated to different carrier proteins.

11. (Currently amended): The immunogenic composition of claim 1 ~~wherein the dried composition is freeze dried~~ further comprising phenol red.

12. (Previously presented): The immunogenic composition of claim 1 wherein the dried composition is freeze dried.

13. (Previously presented): The immunogenic composition of claim 1 wherein the dried composition is a foamed glass.

14. (Previously presented): The immunogenic composition of claims 1 wherein the dried composition is a highly viscous liquid.

15. (Previously presented): The immunogenic composition of claim 14 wherein the highly viscous liquid has not been frozen.

16. (Withdrawn): A method of making a vaccine comprising the step of reconstituting the immunogenic composition of claims 1-15 in an aqueous solution.

17. (Withdrawn): The method of claim 16 wherein the aqueous solution comprises acellular or whole cell Diphtheria toxoid, Tetanus toxoid and Pertussis antigens.

18. (Withdrawn): The method of claim 17 where the DTP vaccine is at least in part adjuvanted with aluminium hydroxide.

19. (Withdrawn): The method of claim 17 wherein the aqueous solution comprises Hepatitis B surface antigen.

20. (Previously presented): A kit comprising the immunogenic composition of claim 1 in one container and liquid acellular or whole cell DTP vaccine in a second container.

21. (Previously presented): The kit of claim 20 further comprising Hepatitis B surface antigen in the second container.

22. (Previously presented): A vaccine comprising the immunogenic compositions of claim 1.

23. (Canceled)

24. (Previously presented): A container with a water repellent internal surface containing the vaccine of claim 22.

25. (Withdrawn): A method of preserving a composition comprising IPV, a bacterial polysaccharide or oligosaccharide and a stabilizing agent comprising the steps of:

- a) preparing a preservation sample by suspending or dissolving IPV and a bacterial polysaccharide or oligosaccharide in a solution of a stabilizing agent;
- b) subjecting the preservation sample to such temperature and pressure conditions that solvent is lost from the preservation sample; and
- c) removing solvent until the preservation sample dries to form a solid or highly viscous liquid in which the antigenicity of IPV is retained.

26. (Withdrawn): The method of claim 25 wherein the preservation sample is dried in a container with a water repellent interior surface.

27. (Withdrawn): The method of claim 25 wherein the preservation sample bubbles to form a foam during step b).

28. (Withdrawn): The method of claim 27, wherein the sample is at least partially frozen before commencing the drying process.

29. (Withdrawn): The method of claim 27 wherein the preservation sample becomes at least partially frozen during step b).

30. (Withdrawn): The method of claim 25 wherein, during step b) the preservation sample is subjected to such temperature and pressure conditions so that the preservation sample loses solvent by evaporation, without freezing or bubbling involved in foam formation, to form a viscous liquid and during step c) solvent is removed until the preservation sample dries to form a highly viscous liquid.

31. (Withdrawn): The method of claim 26 wherein the preservation sample comprises *Haemophilus influenzae* b polysaccharide or oligosaccharide.

32. (Withdrawn): The method of claim 26 wherein the preservation sample comprises polysaccharide or oligosaccharide derived from any of *N. meningitides* A, C, Y or W or combination thereof.